Hematopathologic Correlates of CAR T-Cell Therapy

J Gregory Dolan; Michele E Paessler; Susan R Rheingold; Vinodh Pillai

doi:10.1016/j.cll.2021.03.012

Hematopathologic Correlates of CAR T-Cell Therapy

Clin Lab Med. 2021 Sep;41(3):325-339. doi: 10.1016/j.cll.2021.03.012. Epub 2021 Jul 1.

Authors

J Gregory Dolan¹, Michele E Paessler², Susan R Rheingold¹, Vinodh Pillai³

Affiliations

¹ Division of Oncology and Cellular Therapy, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Division of Hematopathology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Division of Hematopathology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: pillaiv1@chop.edu.

PMID: 34304768
DOI: 10.1016/j.cll.2021.03.012

Abstract

CD19-targeting chimeric antigen rector (CAR) T-cell products are used for the treatment of relapsed/refractory B-acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma. The success of CD19-CAR-T cells has led to the investigation of CAR T-cell products targeting different antigens in other hematological malignancies and solid tumors. Clinical laboratories play an important role in the manufacture, distribution, and monitoring of CAR T-cell therapy. Hence, it is important for laboratory professionals to be cognizant of clinicopathologic aspects of CAR T-cell therapy.

Keywords: B-ALL; CAR T-cell therapy; CD19; Hematopathology; Immunotherapy; Tisagenlecleucel.

Publication types

Review

MeSH terms

Antigens, CD19
Humans
Immunotherapy, Adoptive*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Receptors, Antigen, T-Cell
T-Lymphocytes

Substances

Antigens, CD19
Receptors, Antigen, T-Cell